Compare VRTX & GLW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | GLW |
|---|---|---|
| Founded | 1989 | 1851 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Telecommunications Equipment |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 137.7B |
| IPO Year | 2006 | 2008 |
| Metric | VRTX | GLW |
|---|---|---|
| Price | $447.32 | $176.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 12 |
| Target Price | ★ $539.69 | $146.91 |
| AVG Volume (30 Days) | 1.1M | ★ 11.6M |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 0.74% |
| EPS Growth | ★ 836.54 | 215.52 |
| EPS | ★ 4.02 | 0.43 |
| Revenue | $2,488,652,000.00 | ★ $15,629,000,000.00 |
| Revenue This Year | $10.79 | $20.74 |
| Revenue Next Year | $10.47 | $12.80 |
| P/E Ratio | ★ $111.69 | $426.84 |
| Revenue Growth | ★ 46.20 | 19.14 |
| 52 Week Low | $362.50 | $49.10 |
| 52 Week High | $509.98 | $211.79 |
| Indicator | VRTX | GLW |
|---|---|---|
| Relative Strength Index (RSI) | 58.10 | 47.33 |
| Support Level | $429.02 | $169.80 |
| Resistance Level | $461.66 | $177.92 |
| Average True Range (ATR) | 11.30 | 11.72 |
| MACD | 1.65 | -2.29 |
| Stochastic Oscillator | 70.61 | 13.81 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Corning is a provider of glass, ceramics, and optical fiber across six distinct end markets. Corning's largest segments by revenue are display glass for TVs and optical fiber for telecom networks and data centers. It also provides cover glass for smartphones as well as filters and substrates and glass for cars, produces pharmaceutical glass, and produces polysilicon for solar panels. Corning is a US producer and is vertically integrated across its products and markets.